Literature DB >> 1477389

Drug resistance of Mycobacterium tuberculosis in Korea.

S J Kim1, Y P Hong.   

Abstract

Drug resistance of Mycobacterium tuberculosis has been investigated with isolates from patients screened from a sample population of the nationwide tuberculosis prevalence surveys or from routine cultures. The results showed a close inverse relationship between the prevalence of drug resistance and the efficiency of the past or current National Tuberculosis Control Program (NTP) treatment regimens. Individual drug resistance also showed a close relationship with the extent of use of the relevant drugs. Drug resistance was found in 38.0% of M. tuberculosis isolates from patients in the 1965 survey and remained unchanged until it increased to 48.0% in 1980. The resistance prevalence, however, dropped to 25.3% in the 1990 survey. Such a decrease coincided fairly well with a continuous increase of the treatment efficiency (from 60% in 1984 to 77% in 1989) in the 1980s. Initial drug resistance (IR) also showed a similar trend, namely 26.2% in 1965, 23.9% in 1970, 20.1% in 1975, 30.6% in 1980, 17.4% in 1985 and 15.0% in 1990. A higher prevalence of IR was observed among urban patients than rural patients and among young as opposed to old patients.

Entities:  

Mesh:

Year:  1992        PMID: 1477389     DOI: 10.1016/0962-8479(92)90090-7

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  13 in total

1.  Screening and treatment of immigrants and refugees to Canada for tuberculosis: Implications of the experience of Canada and other industrialized countries.

Authors:  R E Thomas; B Gushulak
Journal:  Can J Infect Dis       Date:  1995-09

2.  Rapid detection of rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis isolates in shanghai by using the amplification refractory mutation system.

Authors:  Xiao-Yong Fan; Zhong-Yi Hu; Fan-Hong Xu; Zhi-Qiang Yan; Sheng-Qi Guo; Zhong-Ming Li
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

Review 3.  Tropical respiratory medicine. 2. Impact of human immunodeficiency virus on tuberculosis in developing countries.

Authors:  P P Nunn; A M Elliott; K P McAdam
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

Review 4.  Treatment and prevention of multidrug-resistant tuberculosis.

Authors:  I Bastian; R Colebunders
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

5.  Detection of rifampin-resistant Mycobacterium tuberculosis in sputa by nested PCR-linked single-strand conformation polymorphism and DNA sequencing.

Authors:  B J Kim; K H Lee; B N Park; S J Kim; E M Park; Y G Park; G H Bai; S J Kim; Y H Kook
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

6.  Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR-single-strand conformation polymorphism analysis for rifampin susceptibility testing.

Authors:  B J Kim; S Y Kim; B H Park; M A Lyu; I K Park; G H Bai; S J Kim; C Y Cha; Y H Kook
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

Review 7.  Tuberculosis at the end of the twentieth century.

Authors:  K A Sepkowitz; J Raffalli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

8.  Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis.

Authors:  Fei Zhao; Xu-De Wang; Luke N Erber; Ming Luo; Ai-zhen Guo; Shan-shan Yang; Jing Gu; Breanna J Turman; Yun-rong Gao; Dong-fang Li; Zong-qiang Cui; Zhi-ping Zhang; Li-jun Bi; Anthony D Baughn; Xian-En Zhang; Jiao-Yu Deng
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

9.  Multiplex detection of mutations in clinical isolates of rifampin-resistant Mycobacterium tuberculosis by short oligonucleotide ligation assay on DNA chips.

Authors:  Jiao-Yu Deng; Xian-En Zhang; Hong-Bing Lu; Qiang Liu; Zhi-Ping Zhang; Ya-Feng Zhou; Wei-Hong Xie; Zhi-Jun Fu
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 10.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.